The Research Into the Effect of SGLT2 Inhibition on Left Ventricular Remodeling in Patients With Heart Failure and Diabetes Mellitus (REFORM) trial was the first to try to determine the mechanistic effect of SGLT2-inhibitors specifically in the HF population. The gene discussed is SLC5A2; the disease is diabetes mellitus.